Surgical management of acute choroidal neovascularization related submacular hemorrhage: Three case reports

doi:10.12998/wjcc.v14.i6.118545

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 6

This Article

(41)

(47)

(0)

(8)

(908)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Feb 26, 2026; 14(6): 118545
Published online Feb 26, 2026. doi: 10.12998/wjcc.v14.i6.118545

Table 1 Summary of cases

Variable	Case 1	Case 2	Case 3
Age/sex	73/M	87/M	89/M
Eye	OD	OS	OS
CNV context	nAMD suspected/treated	nAMD treated (serial IV bevacizumab)	nAMD treated (serial IV aflibercept)
Acute presentation (VA + finding)	CF ^@ approximately 1 m, subretinal bleed	CF ^@ approximately 50 cm, subretinal bleed	LP, subretinal bleed
Intervention	OR-based displacement procedure (PPV + subretinal tPA + gas per protocol)	PPV + subretinal tPA + gas	PPV + subretinal tPA + gas
VA course (early follow-up)	Pre-op: CF ^@ 1 m → POD1: CF ^@ 1 m → POW2: CF ^@ 1.5 m → POW3: HM	Pre-op: CF ^@ 50 cm → POD1: CF near face → POD10: CF < 1 m	Pre-op: LP → POD1: CF ^@ 1 m → POD8: HM
Early postop issue	Hypotony (IOP 2 on POD2)	Ocular hypertension (IOP 27 on POD1)	None
Anti-VEGF	Planned/ongoing	Continued/ongoing	Planned/ongoing
Follow-up duration	6 months	12 months	6 months

CNV: Choroidal neovascularization; OD: Oculus dexter; OS: Oculus sinister; CF: Counting fingers; VA: Visual acuity; LP: Light perception; PPV: Pars plana vitrectomy; tPA: Tissue plasminogen activator; Anti-VEGF: Anti-vascular endothelial growth factor; OR: Operating room.

Full Size Table

Citation: El Mollayess G, Jaroudi M, Tlaiss Y, Itaoui R, Abiad B. Surgical management of acute choroidal neovascularization related submacular hemorrhage: Three case reports. World J Clin Cases 2026; 14(6): 118545
URL: https://www.wjgnet.com/2307-8960/full/v14/i6/118545.htm
DOI: https://dx.doi.org/10.12998/wjcc.v14.i6.118545

El Mollayess G, Jaroudi M, Tlaiss Y, Itaoui R, Abiad B. Surgical management of acute choroidal neovascularization related submacular hemorrhage: Three case reports. World J Clin Cases 2026; 14(6): 118545 [PMID: 41810055 DOI: 10.12998/wjcc.v14.i6.118545]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.